The Chief scientist of the World Health Organisation (WHO) Dr Soumya Swaminathan has said that the overall efficacy of Covaxin is quite high and the phase-3 trials of the vaccine look good. The Hyderabad-based vaccine maker Bharat Biotech had a pre-submission meeting on June 23 and now it is awaiting a nod for an emergency-use listing (EUL) from WHO. A few days ago, Bharat Biotech had released the phase 3 clinical trial results of Covaxin after evaluating 130 symptomatic COVID-19 cases. The age group of the vaccine trial participants ranged from 18-98 years, as per the company. Phase 3 data has found Covaxin to be 77.8% effective against mild, moderate, and severe COVID-19 and 65.2% protection against the new Delta variant.

Source: dna July 09, 2021 04:52 UTC